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Heterologous prime-boosting with viral vectors encoding the
pre-erythrocytic antigen thrombospondin-related adhesion
protein fused to a multiple epitope string (ME-TRAP) induces
CD8+ T cell-mediated immunity to malaria sporozoite chal-
lenge in European malaria-naive and Kenyan semi-immune
adults. This approach has yet to be evaluated in children and
infants. We assessed this vaccine strategy among 138 Gambian
and Burkinabe children in four cohorts: 2- to 6-year olds in
The Gambia, 5- to 17-month-olds in Burkina Faso, and 5- to
12-month-olds and 10-week-olds in The Gambia. We assessed
induction of cellular immunity, taking into account the distinc-
tive hematological status of young infants, and characterized
the antibody response to vaccination. T cell responses peaked
7 days after boosting with modiﬁed vaccinia virus Ankara
(MVA), with highest responses in infants aged 10 weeks at
priming. Incorporating lymphocyte count into the calculation
of T cell responses facilitated a more physiologically relevant
comparison of cellular immunity across different age groups.
Both CD8+ and CD4+ T cells secreted cytokines. Induced anti-
bodies were up to 20-fold higher in all groups compared with
Gambian and United Kingdom (UK) adults, with comparable
or higher avidity. This immunization regimen elicited strong
immune responses, particularly in young infants, supporting
future evaluation of efﬁcacy in this key target age group for a
malaria vaccine.
INTRODUCTION
Vaccination is one of the most cost-effective health care interven-
tions available, and currently used vaccines prevent an estimated
2.5 million deaths each year.1 Most vaccines are administered during
infancy and protect primarily through the induction of antibodies.2,3
The exception is Bacille Calmette-Guérin (BCG), where protection
appears to involve mainly CD4+ T cells. However, there is a range
of diseases affecting infants, for which vaccines are yet to be devel-
oped, where an ability to induce potent CD8+ T cell responses could
be important. These include respiratory syncytial virus (RSV), HIV,
tuberculosis, and vaccines targeting malaria parasites at the liver stage
of infection.4 An extensive literature in murine immunology docu-
ments frequent reductions in CD8+ T cell induction in newborn
mice, suggesting that generation of such T cell responses in human
infants might be difﬁcult.5–8 Limited studies in infants demonstrate
reduced Th1 and proliferative responses to vaccination;9–11 however,
data are lacking on the capacity to induce CD8+ T cells in early
infancy.
A highly effective malaria vaccine against the most lethal malaria spe-
cies, Plasmodium falciparum, could help to save half a million lives
each year.12 The primary target population for a vaccine is young in-
fants in sub-Saharan Africa because from 6months of age, infants and
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children in this region bear the greatest burden of malaria mortality.12
Themost advancedmalaria vaccine, RTS,S/AS01, shows good efﬁcacy
against controlled human malaria infection (CHMI) in adults in the
United States,13,14 however, efﬁcacy against clinical malaria observed
among 6- to 12-week-old infants in a large phase 3 clinical trial was
30% over 12 months,15,16 and declined thereafter, well below the
target of 75% efﬁcacy against clinical malaria speciﬁed by the updated
Malaria Vaccine Technology Roadmap.17,18 RTS,S/AS01 does not
induce CD8+ T cells; efﬁcacy is mediated by IgG antibodies and
CD4+ T cells against the circumsporozoite (CS) protein, a pre-eryth-
rocytic antigen that is highly abundant during the sporozoite stage of
the parasite life cycle.19–22 Immunogenicity data from efﬁcacy trials
demonstrated that the levels of anti-CS antibodies induced in 6- to
12week-old infants were 3-fold lower than in 5- to 17-month-olds,
suggesting that RTS,S/AS01 is less immunogenic in young in-
fants.15,23 This stage of the parasite life cycle is an attractive target
for a humoral response as sporozoites can be eliminated before infect-
ing host hepatocytes, however, this window may be as brief as
30min.24 The liver-stage of the P. falciparum life cycle is also a leading
target for vaccination. This stage lasts between 5.5 and 7 days in
humans,25–27 thus prolonging the opportunity for antigen-speciﬁc
CD8+ T cells to locate and kill infected hepatocytes.
We have previously described vaccination approaches employing the
sporozoite antigen thrombospondin-related adhesion protein
(TRAP) fused to a multiple epitope string (ME) in a number of deliv-
ery platforms including DNA and replication-deﬁcient viral vectors.28
Most recently, we have demonstrated the safety and immunogenicity
of a heterologous prime-boost approach using a chimpanzee adeno-
virus (ChAd63) andmodiﬁed vaccinia virus Ankara (MVA), both en-
coding the ME-TRAP subunit.29–31 This regimen induces cellular
immunity comprising both CD4+ and CD8+ phenotypes and IgG
antibody responses in malaria-naive and semi-immune adults.32,33
Against CHMI with P. falciparum-infected mosquitoes, ChAd63
MVAME-TRAP elicited 21% sterile efﬁcacy and signiﬁcantly delayed
the time-to-patency of malaria in a further 36% of vaccinees.34 Efﬁ-
cacy was strongly associated with monofunctional interferon-gamma
(IFNg)-secreting CD8+ T cells. In a recent ﬁeld trial in Kenyan adults,
67% efﬁcacy against malaria infection was induced by the same im-
munization regime, and again, a T cell correlate of efﬁcacy was
observed.35 Signiﬁcant anti-TRAP IgG titers after heterologous
prime-boost with ChAd63 ME-TRAP and MVA ME-TRAP could
also contribute to vaccine efﬁcacy.33
We present here a detailed evaluation of the high-level T cell and anti-
body responses induced by this regimen in young children and in-
fants. Infants have very different hematological parameters to older
children and adults: total blood volume is substantially lower and
numbers of circulating lymphocytes per ml signiﬁcantly higher.36
We propose an alternative approach for calculating T cell responses
following vaccination, which takes account of the higher lymphocyte
count in infants and young children. This methodology is especially
relevant when comparing cellular immunogenicity across age groups.
Here, we report T cell and antibody immunogenicity across four pe-
diatric age strata ranging from 6 years to 10 weeks old, from three
clinical vaccine studies using the ChAd63 ME-TRAP and MVA
ME-TRAP regimen in malaria-exposed African children and infants.
Responses are also compared to those of malaria-naive and malaria-
exposed vaccinated adults. Given that each clinical trial was a small
phase I study, combining the datasets together into a single analysis
facilitates the observation of trends across age groups and between co-
horts with differing malaria exposure. Two clinical trials were per-
formed in the western region of The Gambia in Sukuta, where modest
malaria transmission is still observed following seasonal rains, despite
a substantial decline in incidence since 2003.37 A third study was un-
dertaken in Burkina Faso with highly seasonal transmission and a far
greater incidence of malaria than in The Gambia, averaging more
than one conﬁrmed clinical episode per child per year.38,39 An effec-
tive malaria vaccine would be useful in both settings.
RESULTS
Study Design
Two hundred children were screened for eligibility across the three
trials and 138 eligible children were enrolled, vaccinated, and fol-
lowed up (Figures S1A and S1B) Trial groups are shown in Table 1.
Primary outcomes of safety, reactogenicity, dose-ﬁnding, and pre-
liminary cellular immunogenicity from this study are reported
separately.40 Baseline demographics of trial participants are shown
in Table S1.
Immunogenicity
T Cell Responses Assessed by ELISpot
We report elsewhere ex vivo IFNg ELISpot responses stratiﬁed by age
and dose in group 1 and group median response data stratiﬁed by
dose in groups 2, 3, and 4.40 Peak ELISpot responses were compared
Table 1. Study Outline
Group Age Site N
1st Vaccine Dose
ChAd63
ME-TRAP, vp
2nd Vaccine
Dose MVA
ME-TRAP, PFU
1a
2–6 years The Gambia
6 1  1010 1  108
1b 6 1  1010 2  108
1c 6 HDCRV (1 mL) HDCRV (1 mL)
1d 6 5  1010 1  108
1e 6 5  1010 2  108
1f 6 HDCRV (1 mL) HDCRV (1 mL)
2a
5–12 months The Gambia
12 1  1010 1  108
2b 12 5  1010 1  108
2c 12 no vaccine no vaccine
3a
10 week The Gambia
12 1  1010 1  108
3b 12 5  1010 1  108
3c 12 no vaccine no vaccine
4 5–17 months Burkina Faso 30 5  1010 1  108
vp, viral particles; PFU, plaque-formingunits;HDCRV, humandiploid cell rabies vaccine.
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between groups in these age de-escalation studies with those from
previously published adult phase I trials in the United Kingdom34
and The Gambia.32 A trend toward lower T cell immunogenicity in
pediatric vaccinees compared with adult vaccinees was measured,
with responses in Burkinabe children signiﬁcantly reduced (Fig-
ure 1A). Notably, responses in 10-week-old Gambian infants were
comparable to those in adults and higher than in Burkinabe children
aged 5–12 months and 13–17 months (Figure 1A; p < 0.0001, Krus-
kal-Wallis test with Dunn’s correction for multiple tests). No differ-
ences were measured between responses in United Kingdom (UK)
and Gambian adults (data not shown32). Due to the observation
that children under 17 months have signiﬁcantly higher lymphocyte
counts per milliliter of blood than older children and adults (Fig-
ure 1B; p < 0.0001, Kruskal-Wallis test with Dunn’s correction for
multiple tests), expressing ELISpot responses using the number of pe-
ripheral blood mononuclear cells (PBMC) as the denominator may
not accurately reﬂect immunogenicity across age groups. We there-
fore express ELISpot responses as spot-forming cells (SFC) per milli-
liter of blood by integrating lymphocyte counts collected during
routine hematology tests at each time point. Using this arguably
more physiologically relevant denominator, T cell responses were
comparable between adults, children, and older infants. Furthermore,
responses in 10-week-old infants were almost 3-fold higher than UK
and Gambian adults (Figure 1C, p = 0.0017, Kruskal-Wallis test with
Dunn’s correction for multiple tests against adult control group). No
differences were measured between responses in UK and Gambian
adults (data not shown). Responses remained higher in Gambian
10-week-old infants compared to both Burkinabe age groups (Fig-
ure 1C; p = 0.0007, Kruskal-Wallis test with Dunn’s correction for
multiple tests between all pediatric groups).
T Cell Responses Assessed by Flow Cytometry
Flow cytometry is reported for samples from Gambian 5- to
12-month-olds and Burkinabe 5- to 17-month-olds. Due to limited
PBMC availability and technical issues with the assay, older children
and young infants were not assessed. Assessment of cytokine ex-
pression 7 days after boosting with MVA ME-TRAP showed detect-
able IFNg, interleukin 2 (IL-2), and tumor necrosis factor-alpha
(TNF-a) secretion from CD4+ and CD8+ T cells (Figure 2).
A
B
C
Figure 1. ELISpot Responses across Trials with Age De-escalation
(A) Comparison of peak ELISpot immunogenicity at 7 days post-MVA including data
from previously published trials in adults,32,34 expressed as SFC per 106 PBMC
(Kruskal-Wallis test with Dunn’s post-test for multiple comparisons between all
groups. Dotted lines show lower limit of assay detection (LLD) and positive threshold
for ELISpot response. (B) Lymphocyte counts per milliliter of blood for all vaccinated
volunteers. (Kruskal-Wallis test with Dunn’s post-test for multiple comparisons
between all groups. Adult groups not combined due to difference by 2-tailed Mann-
Whitney test, p = 0.0009). (C) ELISpot responses expressed as SFC per milliliter of
blood (Kruskal-Wallis test with Dunn’s post-test for multiple comparisons to adult
control group denoted by black bars, Kruskal-Wallis test with Dunn’s post-test for
multiple comparisons between all pediatric groups denoted by gray bars). Closed
circles, UK adults; open circles, Gambian adults; open triangles, all pediatric
groups. Numbers in green and group bars represent group medians. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
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Expression of the degranulation marker CD107a on CD8+ T cells was
also evident in 15% of volunteers tested.
Antibody Responses after Vaccination
Antibody responses to vaccination in Gambian 2- to 6-year-olds
(group 1) were weak, irrespective of priming or boosting dose (Fig-
ure 3A). IgG titers in Gambian and Burkinabe infants and young chil-
dren (groups 2, 3, and 4) markedly increased 7 days after boosting
with MVA (Figure 3B). In Gambian 10-week-olds (group 3), IgG ti-
ters were signiﬁcantly higher post-boost in the group that received the
higher dose of ChAd63 ME-TRAP (p = 0.0008, 2-tailed Mann Whit-
ney test, group 3a versus 3b), however, there were no signiﬁcant ef-
fects of ChAd63 ME-TRAP dose in other age groups (Figure 3B). Re-
sponses in all groups of infants and children under 2 years were very
substantially and signiﬁcantly higher than responses in UK and Gam-
bian adults (Figure 3C; p = < 0.0001, Kruskal-Wallis test with Dunn’s
correction for multiple tests comparing between all groups). Re-
sponses in Gambian 2- to 6-year-olds (group 1) were similar in
magnitude to those in adults. IgG subtypes were also measured for
each group. IgG1 and IgG3 subclasses showed the highest increase
above baseline, with signiﬁcantly higher titers in infants and young
children (groups 2, 3, and 4) than older children (group 1) or adults
(Figures 3D and 3E). Titers of IgA antibodies at the peak of the im-
mune response were more frequently detected in the Burkinabe in-
fants, than in the Gambian groups (Figure 3F). IgM antibody re-
sponses were low after vaccination and did not vary between
groups (data not shown).
Avidity of IgG antibodies was measured at the peak time point (Fig-
ure 4A) and was signiﬁcantly higher in Burkinabe infants and chil-
dren when compared with Gambian 10-week-olds (p = 0.0006, Krus-
kal-Wallis test with Dunn’s correction for multiple tests). A similar
trend in IgG avidity was seen in Gambian 5- to 12-month-olds
Figure 2. T Cell Responses by Flow Cytometry
Responses were assessed from cryopreserved PBMC for
group 2 (5- to 12-month-olds in the Gambia, N = 8) and
group 4 (5- to 17-month-olds in Burkina Faso, N = 12).
Dotted lines represent the lower limit of detection for
CD4+ and CD8+ T cell populations. Bars represent geo-
metric means. Open symbols, group 2; closed symbols,
group 4.
compared to Gambian 10-week-olds. Children
aged 2–6 years (group 1) were not included in
this analysis due to the low number of individ-
uals with high enough titers to perform the
assay. Differences in antibody avidity between
groups were further studied by measuring the
avidity of IgG1 and IgG3 subtypes in younger
children and infants (groups 2, 3, and 4; Figures
4B and 4C), which revealed that the lower IgG
avidity in 10-week-olds was largely due to lower
avidity of IgG1 antibodies as IgG3 avidity was
comparably low across all groups of infants and children. Avidity of
IgG1 antibodies was highest in Gambian infants aged 5–12 months
and signiﬁcantly higher than that in Burkinabe infants of comparable
age (Figure 4B; p < 0.0001, Kruskal-Wallis test with Dunn’s correction
for multiple tests). A clear effect of age was apparent in Burkinabe
5- to 17-month-olds (group 4), in which IgG1 avidity was positively
associated with age at ﬁrst vaccination (Spearman’s r = 0.47, p 0.02,
Figure 4D). Total IgG avidity signiﬁcantly increased between 1 and
7 weeks post-boost in both Gambian 5- to 12-month-olds and
10-week-olds (p = 0.0015 and p = 0.0010, respectively, Wilcoxon
matched pairs test between time points within the same group, Fig-
ure 4E). The magnitude of the increase in avidity after boosting was
the same for both age groups with the ratio of the avidity at 7 weeks
to 1 week post-boost comparable for 5- to 12-month-olds and
10-week-olds (Figure 4F).
Neutralizing antibodies to the adenovirus vector were measured prior
to vaccination in group 1 only and were weaker than those measured
previously in Gambian adults (74 ELISA units [EUs], 95% conﬁdence
interval [CI] 35–155 in group 1 versus 192 EUs, 95% CI 104–422).32
Neutralizing antibody titers were not correlated with T cell or anti-
body responses at the peak time point 7 days after MVA ME-TRAP
vaccination (Figures 4G and 4H).
DISCUSSION
We demonstrate here that immunization of children and infants with
a prime-boost regimen using ChAd63 and MVA ME-TRAP induces
high level T cell and antibody responses to a pre-erythrocytic malaria
antigen that has previously demonstrated efﬁcacy against CHMI in
malaria naive adults and against natural infection in semi-immune
adults.33–35 Levels of TRAP-speciﬁc T cells and IgG were highest in
infants who received their priming immunization at 10 weeks of
age and an MVA ME-TRAP boost 8 weeks later.
Molecular Therapy
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Figure 3. Antibody Responses to Vaccination
(A) Geometric mean time course of anti-TRAP IgG for Gambian 2- to 6-year-olds (group 1) vaccinated with high and low dose ChAd63 ME-TRAP and MVA ME-TRAP. (B)
Geometric mean time course of anti-TRAP IgG titer for Gambian 5- to 12-month-olds (group 2), Gambian 10-week-olds (group 3) and Burkinabe 5- to 17-month-olds (group
4). (C) Peak IgG titer at 7 days post-MVA. (D and E) TRAP-specific IgG1 and IgG3 antibodies at day 63 (1 week post-MVAME-TRAP). (F) TRAP-specific IgA antibodies at day
(legend continued on next page)
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Higher ELISpot responses were measured in adults vaccinees
compared to pediatric vaccinees using the standard ELISpot readout.
However, comparisons of immunogenicity in de-escalating age
groups are complex due to differences in body mass and total blood
volume of participants receiving similar doses of vaccine. More spe-
ciﬁcally, variations are observed in the numbers of lymphocytes circu-
lating per milliliter of blood between adults and children and between
infants and older children. To address this, we have incorporated the
lymphocyte count from the full blood count performed at the same
time into the denominator of the units used to report ELISpot re-
sponses. Using this approach to take account of the much higher
lymphocyte frequencies measured in young children and infants,
we have quantiﬁed comparable T cell responses between adults, chil-
dren, and older infants. Responses in 10-week-old infants were almost
3-fold higher compared with adults, indicating that ChAd63 and
MVAME-TRAP T cell immunogenicity is increased and not reduced
with administration to young infants.
While T cell responses between the two sites were comparable be-
tween 5- to 17month-olds, overall lower responses were measured
in Burkina Faso, potentially due to a combined effect of age and
differing malaria exposure by site. Malaria-related immunosuppres-
sion could lead to reduced vaccine immunogenicity or differences
in innate immunity may exist in the early weeks of life in these chil-
dren. Congruently, malaria transmission in the Gambia is markedly
lower than in Burkina Faso,37,39,41 thus these effects would likely be
seen in older Gambian children who have had more years of lower
level malaria exposure; and in younger infants in Burkina Faso where
transmission is higher.42,43
Higher frequencies of antigen-speciﬁc cells per milliliter of blood traf-
ﬁcking through the spleen may increase the likelihood of antigen
recognition from antigen-presenting cells following vaccination, giv-
ing rise to greater cellular immunity. The level of antigen-speciﬁc
T cells per milliliter is likely to correlate better with vaccine efﬁcacy
than T cells per million PBMC, as the former should correlate better
with the rate at which antigen-speciﬁc T cells enter the liver, which is
the relevant target organ in malaria.
Anti-TRAP IgG titers at the peak time point were, remarkably,
20-fold higher in the youngest groups of children and infants
than those at the same time point post-vaccination in malaria-naive
and semi-immune adults. Interestingly, titers in 2- to 6-year-old chil-
dren were lower than those in adults and younger children or infants,
which when assessed in combination with the similar observation in
T cell frequencies, suggests vaccination of older children may be less
effective at preventing malaria infection. A recent study with these
viral vectors expressing TRAP and circumsporozoite protein (CS)
in malaria-naive adults, proposed a role for both anti-CS and anti-
TRAP antibody responses in reducing parasite density during the
liver-stage of malaria infection.33 This suggests that the additional
component of antibody immunogenicity elicited in the youngest
age groups here may improve the efﬁcacy of this vaccine regime
to a level above that observed in adults undergoing CHMI. In
RTS,S/AS01 trials a reduction of anti-CS IgG responses in a compa-
rable group of 6- to 12-week-old infants compared with adults
associated with decreased vaccine efﬁcacy.44 The ﬁnding that viral-
vector-induced antibody levels are not decreased in this age group
is therefore very encouraging, because this is the preferred target
age group for a malaria vaccine.
Avidity of antibodies measured 7 days after boosting was lower in
young infants than in 5- to 12- or 5- to 17-month-olds, although
the kinetics of avidity maturation were comparable between these
age groups. In the Burkinabe infants, IgG1 avidity was signiﬁcantly
lower than in Gambian infants of the same age, perhaps again due
to increased malaria exposure in Burkina Faso. Avidity of IgG anti-
bodies alone has been shown not to be predictive of malaria vaccine
efﬁcacy for RTS,S/AS01, however, an association between the change
in avidity, as well as IgG titers following the second and third dose
were strongly associated with a reduction in the risk of malaria.45
This suggests that the kinetics of antibody avidity maturation as
well as the magnitude of the IgG response contributes to vaccine ef-
ﬁcacy. Further work to determine the potential for antibodies induced
by this regime to inhibit parasite invasion using in vitro functional as-
says is underway.
Previous studies have demonstrated a reduction of cellular responses
to vaccines in infants with reduced or defective secretion of Th1 cy-
tokines in response to oral polio and protein-in-adjuvant vaccines,
such as DTaP.10,11,46 Similarly, preferential differentiation of B cells
into memory cells rather than plasma cells is associated with reduced
IgG responses to protein and polysaccharide antigens in infants.8,47
The preliminary observations reported here demonstrate that replica-
tion-deﬁcient viral vectors can elicit immune responses in infants that
appear to be superior to those in comparable adult populations. De-
livery of antigens by viral vectors may overcome the limitations of the
immature infant immune system, which have been shown to limit
seroconversion to EPI vaccines.48,49 This is consistent with strong
CTL function previously measured following congenital infection
with cytomegalovirus and Trypanosoma cruzi, demonstrating that
under certain conditions, the immature human immune system is
indeed capable of potent CTL activity.50,51
In this study, we have assessed the ability of a virally vectored prime
boost regime to induce immunity to a protective pre-erythrocytic ma-
laria antigen in two populations with very different malaria endemic-
ities. Furthermore, a novel methodology for more physiological and
63. Dashed lines show seropositive threshold (mean + 3 SD of 42 malaria-naive samples tested on each assay). Closed circles UK adults at peak; open circles Gambian
adults at peak; open triangles all pediatric groups at peak. All adults boosted with 2  108 PFU MVA ME-TRAP, all children and infants boosted with 1  108 PFU MVA
ME-TRAP. Medians displayed. All comparisons across groups made using Kruskal-Wallis with Dunn’s post-test for multiple comparisons to adult control group. *p < 0.05.
**p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 4. Antibody Avidity and Anti-Vector
Neutralizing Antibodies
(A) Avidity of total IgG (B), IgG1 and (C) IgG3 subtypes in
Burkinabe and Gambian younger children and infants
(groups 2, 3, and 4) and adults (Kruskal-Wallis test with
Dunn’s post-test for multiple comparisons between all
groups). (D) Effect of age at first vaccination on IgG1
antibody avidity after boosting in Burkinabe 5- to
17-month-olds (group 4, Spearman’s r = 0.47, p 0.02).
(E) Increase in total IgG avidity between 1 and 7 weeks
post boost, (p = 0.0015 for 5- to 12-month-olds,
p = 0.0010 for 10-week-olds, Wilcoxon matched pairs
for comparisons within groups. Mann Whitney test with
post-test for multiple comparisons between groups at
comparable time points). (F) Change in total IgG avidity
between 1 and 7 weeks post boost, expressed as a ratio
for each age group (no significant difference by t test).
(G and H) Correlations between group 1 neutralizing
antibody titers to the ChAd63 vector and peak antibody
titers by ELISA and T cell responses by ELISpot, respec-
tively. Spearman’s r = 0.06, p 0.75 for (G) and r = 0.002,
p 0.99 for (H). Medians displayed. Kruskal-Wallis tests
performed with Dunn’s post-test for multiple comparisons
between all groups. *p < 0.05. **p < 0.01, ***p < 0.001,
****p < 0.0001.
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robust comparison between adult and pediatric T cell responses was
developed and applied across several age de-escalating clinical studies.
Our immunogenicity ﬁndings combined with the acceptable safety
proﬁle observed in these studies40 show clear potential utility of this
approach for immunization against malaria and other childhood ill-
nesses where either antibodies or cellular immunity are relevant to
protection, for example RSV.52 Further studies are underway to assess
optimal regimes for immunization with co-administration of WHO
Expanded Program of Immunisation (EPI) vaccines and to determine
efﬁcacy against clinical and severe malaria in a cohort of infants and
children in a region of high malaria transmission.
MATERIALS AND METHODS
Objectives
The primary objective of these trials was to evaluate the safety and re-
actogenicity of the ChAd63ME-TRAP andMVAME-TRAP vaccines
in malaria-experienced Gambian and Burkinabe children. Secondary
objectives were to evaluate the cellular and humoral immunogenicity
of the vaccines in two settings of varying seasonalmalaria transmission
while the tertiary objective was to compare the immunogenicity of the
low and high doses of MVA ME-TRAP (Gambian children only).
Study Setting
The ﬁrst clinical trial (group 1) took place from December 2010 to
December 2011 in the Sukuta ﬁeld site of Medical Research Council,
The Gambia. Sukuta is a peri-urban Gambian village located about
30 km south of the capital Banjul. The Sukuta ﬁeld site previously
served as the base for the phase I trials of ChAd63 MVA ME-TRAP
vaccine regimen in adults (18). In this region, malaria transmission is
highly seasonal, occurring almost exclusively during the rainy season
(July to December) with greatest incidence from September to
November. Anopheles gambiae is the principal malaria vector. Previ-
ous studies have documented decline in incidence of malaria in The
Gambia.37,41 The second clinical trial (groups 2 and 3) took place
in the same setting between September 2011 and March 2013.
The third clinical trial (group 4) took place from December 2012 to
September 2013 in Banfora Health District in the Cascades region
of South Western Burkina Faso, about 400 km southwest from the
capital Ouagadougou. Malaria transmission is stable during the
year, with increased levels during the rainy season from May to
November, peaking fromMay to September.38 A. gambiae is the prin-
cipal malaria vector. Immunogenicity analyses of group 4 are split
into two age groups: 5–12 months and 13–17 months, permitting
direct analysis of 5- to 12-month-olds in the Gambia and Burkina
Faso.
Ethics and Regulatory Approval
An independent Data Safety and Monitoring Board (DSMB) was ap-
pointed before the trials began to provide oversight and to review the
safety data reports as the trials progressed. Experienced local pediatri-
cians served as local safety monitors (LSM) and, along with the
DSMB, reviewed all safety data between dose escalations. In addition,
trials were conducted according to ICH Good Clinical Practice guide-
lines and were monitored by an external organization (Appledown
Clinical Research). The Gambian Government/Medical Research
Council Joint Ethics Committee, The Gambia Medicines Board, the
Burkina Faso Ministry of Health and Institutional Bioethics Commit-
tee, the UKMedicines andHealthcare products Regulatory Authority,
and Oxford Tropical Research Ethics Committee (OXTREC
Numbers: 64-09, 26-11, 41-12) granted approval of the study proto-
col. All three trials were registered with https://clinicaltrials.gov
(NCT01373879, NCT01450293, NCT01635647) and the Pan African
Clinical Trials Registry (www.pactr.org) (PACTR201204000362870,
PACTR201401000363170, PACTR201208000404131).
Study Design
We conducted three phase Ib studies. The ﬁrst study (group 1, aged
2–6 years) in The Gambia was the pediatric arm of a phase Ib sin-
gle-blind, randomized controlled, dose-escalation study in adults
that has been reported previously.31,32 The second study, also in
The Gambia, was a subsequent single-blind randomized controlled,
dose-escalation study in children aged 5–12 months (group 2) and
10 weeks (group 3) at vaccination with ChAd63ME-TRAP. The third
study was a phase I open-label safety lead-in group of a larger phase
IIb study in Burkina Faso in children aged 5–17 months at ﬁrst vacci-
nation (group 4). CONSORT diagrams are provided in the Supple-
mental Information. Protocol S1 (group 1, The Gambia), protocol
S2 (groups 2 and 3, The Gambia), protocol S3 (group 4, Burkina
Faso), and checklists S1–S3 are given in the supplemental information
of the paper reporting the clinical outcomes of these studies.40 All vac-
cinations were intramuscular with group 1 receiving doses in the del-
toid region of the arm, while all other groups were vaccinated in the
anterolateral thigh. A control group was added to group 1 because of
the anticipated high frequency of concurrent diseases in the study age
group of 2–6 years and also to aid objective assessment of the relation-
ship of adverse events to vaccination. Human diploid cell rabies vac-
cine (HDCRV) (Sanoﬁ Pasteur MSD) was chosen as the comparator
vaccine because rabies is endemic in The Gambia and anti-rabies vac-
cines were not readily accessible for pre-exposure prophylaxis; hence,
the investigators deemed that giving HDCRVmight beneﬁt the study
participants. In groups 2 and 3, no-treatment controls were included,
but there was no control group in group 4 as the subsequent larger
phase II study had a rabies vaccine control arm. For group 1,
36 eligible children were randomized to receive either group 1a: low
dose ChAd63 ME-TRAP (1  1010vp) followed by low dose MVA
ME-TRAP (1  108 plaque-forming units [ PFU]); group 1b: low
dose ChAd63 ME-TRAP (1  1010vp) followed by high dose
MVAME-TRAP (2 108 PFU); group 1c: control HDCRV 1mL fol-
lowed by HDCRV 1 mL; group 1d: high dose ChAd63 ME-TRAP
(5  1010vp) followed by low dose MVA ME-TRAP (1  108
PFU); group 1e: high dose ChAd63 ME-TRAP (5 1010vp) followed
by high dose MVA ME-TRAP (2  108 PFU); group 1f: Control
HDCRV 1 mL followed by HDCRV 1 mL intramuscular (IM). All
vaccinations were separated by an 8-week interval.
For groups 2 and 3, 36 eligible children in each group were ran-
domized to receive either group a: low dose ChAd63 ME-TRAP
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(1  1010vp) followed by low dose MVA ME-TRAP (1  108 PFU);
group b: high dose ChAd63 ME-TRAP (5  1010vp) followed by low
dose MVAME-TRAP (1 108 PFU); group c: no vaccine. For group
4, all children received high dose ChAd63 ME-TRAP (5  1010vp)
followed by low dose MVA ME-TRAP (1  108 PFU).
Pediatric groups are compared to malaria naive adult vaccinees in the
UK and semi-immune adult vaccinees the Gambia, who all received
5  1010 viral particles (vp) ChAd63 ME-TRAP and 2  108 PFU
MVA ME-TRAP.
Randomization in Groups 1, 2, and 3 and Blinding
An independent statistician at the Centre for Statistics in Medicine,
Oxford performed a stratiﬁed randomization of participants (strati-
ﬁed by age into two categories and split by the median values of
ages of children recruited). The list of eligible children after screening
was sent to the statistician who carried out the randomization. The
statistician had no knowledge of the participants, except the age, as
this was required for the stratiﬁcation. The children were randomly
allocated to six groups in dose-escalated fashion. This was done to
determine the tolerable doses as this was the ﬁrst time ChAd63 and
MVA ME-TRAP vaccines were being administered in Gambian chil-
dren. The investigators and the vaccinators were un-blinded to the
group allocations. However, the study children’s parents/carers
and ﬁeld workers who conducted post-vaccination assessment of re-
actogenicity and solicited symptoms were blinded to the group
allocations.
Sample Size
These phase Ib trials were not powered to detect differences between
groups. The sample size was based on general acceptance of this size
for initial assessment of safety, tolerability, and immunogenicity of
the investigational vaccines in a malaria endemic area and this size
balances the need to avoid exposing a large group of study partici-
pants to an unknown risk with the need for useful safety and immu-
nogenicity data from an adequate sample size.
Interventions
The Clinical Biomanufacturing Facility (CBF; University of Oxford,
UK) and IDT (Germany) manufactured ChAd63 ME-TRAP and
MVA ME-TRAP respectively under Good Manufacturing Practice
conditions, respectively as previously described.34
Blood Processing
Blood samples were stored at room temperature prior to processing,
which was completed within 6 hr of venepuncture. PBMC were sepa-
rated by density centrifugation from heparinized whole blood and re-
suspended in RPMI containing 10% heat-inactivated, batch-tested,
sterile-ﬁltered fetal bovine serum (FBS) previously screened for low
reactivity (Labtech International), 1% L-glutamine, and 1% peni-
cillin/streptomycin. Cell counts were performed using trypan blue
staining and a microscope according to an established standard oper-
ating procedure (SOP) in the lab.
Ex Vivo IFNg ELISpot Assays
Ex vivo (18 hr stimulation) ELISpot assays were performed using
Multiscreen IP ELISpot plates (Millipore), human IFNg SA-ALP
antibody kits (Mabtech), and BCIP NBT-plus chromogenic substrate
(Moss Inc.). Cells were cultured in RPMI (Sigma) containing 10%
heat-inactivated, sterile-ﬁltered fetal calf serum, previously screened
for low reactivity (Labtech International) supplemented with 1%
L-glutamine and 1% penicillin/streptomycin. Antigens were tested
in duplicate with either 200,000 or 250,000 PBMC added to each
well of the ELISpot plate. TRAP peptides were 20 amino acids in
length, overlapping by 10 amino acids (NeoBioLab), assayed in six
pools of seven to ten peptides at 10 mg/mL. Plates were counted using
an AID automated ELISpot counter (AID Diagnostika GmbH, algo-
rithm C), using identical settings for all plates, and counts were
adjusted only to remove artifacts. Responses were averaged across
duplicate wells, responses in unstimulated (negative control) wells
were subtracted from each individual pool, then responses to individ-
ual pools were summed for each strain of the TRAP antigen. Re-
sponses to the negative control were always <142 SFC/106 PBMC,
with a median of 18 SFC/106 PBMC. Pools were considered positive
if the response was greater than the median plus 2 SDs (59 SFC/106)
of all negative control wells after subtraction of the autologous back-
ground. The lower limit of detection for the assay was 28 SFC for
ME-TRAP. Staphylococcal enterotoxin B (0.02 mg/mL) and phyto-
hemmagglutinin-L (10 mg/mL) were used as a positive control,
whereby responses of >800 SFC/106 passed quality control (QC). Re-
agents and methods were standardized between the two trial sites.
Lymphocyte counts per milliliter of blood were taken directly from
the hematology breakdown or calculated by multiplying the number
of white blood cells per milliliter of blood by the lymphocyte differen-
tial percentage. These data were routinely obtained at post-vaccina-
tion time points as part of the safety assessments. This value was
then multiplied by the number of SFC per million PBMC to produce
the number of SFC per milliliter of blood.
Flow Cytometry
PBMC were frozen in FBS containing 10% DMSO and stored in the
vapor phase of liquid nitrogen. Of the 30 PBMC samples available in
group 4, we selected samples where the ELISpot on fresh PBMC at day
gave a response over 250 SFC per million PBMC, as responses lower
than this would not be detectable by ﬂow cytometry.
Thawing was performed rapidly in a water bath and cells were rested
for 2 hr with benzonase at 25 U/106 PBMC (Novagen) before stimu-
lation overnight at 37C with 5% CO2, either with Staphylococcal
enterotoxin B, a pool of 56 peptides at 2 mg/mL spanning the entire
length of the TRAP protein from the T9/96 strain of P. falciparum
(Neopeptide) or an unstimulated control. Brefeldin A (BD Biosci-
ences) 1 mg/mL and monensin (eBioscience) 1 mg/mL were added af-
ter 2 hr into the incubation and left to incubate for a further 16 hr.
Cells were then washed in ﬂuorescence-activated cell sorting
(FACS) buffer (PBS containing 0.1% bovine serum albumin [BSA]
and 0.01% sodium azide and stained for viability with LIVE/DEAD
aqua amine reactive dye (Life Technologies) for 20 min at room
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temperature in the dark. Cells were then washed in FACS buffer and
permeabilized for 20 min with Cytoﬁx/Cytoperm (BD Biosciences)
then washed in 1:10 permeabilization buffer (BD Biosciences).
A cocktail of antibodies for surface and intracellular staining was
added and incubated for 30 min at room temperature in the dark.
The antibody cocktail is described in Table S2. Cells were again
washed in permeabilization buffer and resuspended in PBS contain-
ing 1% paraformaldehyde, prior to acquisition on a BD LSR II on
the day of staining. Compensation control beads (OneComp Beads,
eBioscience, ArC Amine Reactive Beads, Invitrogen) were stained ac-
cording to the manufacturer’s instructions using the same concentra-
tion of antibody used for cells to for compensation between parame-
ters, and unstained cells were used to adjust forward and side scatter
photo-multiplier tube voltages.
Analysis of Flow Cytometry Data
At least 29,000 live CD3+ cells were analyzed per sample. Data were
prepared and analyzed using FlowJo v9.6.2 (Treestar) with a hierarchi-
cal gating strategy. A sample gating strategy is shown in Figure S2. Re-
sponses to peptidewere determined after subtraction of the response in
the unstimulated control for each sample. Samples where a response to
the positive control of >1% cytokine positive CD4+ or CD8+ T cells af-
ter subtraction of the unstimulated control could not be detected were
excluded from the analysis. All samples had a minimum of 31,000
CD4+ or 8,000 CD8+ T cells in the parent population, thus the lower
limit of detection for the assay was 0.0042% for CD4+ T cells and
0.022% for CD8+ T cells. A response was classiﬁed as positive if the
response to peptide was greater than the medium control for the cor-
responding sample. Analysis of polyfunctionality was not undertaken
due to low event numbers acquired from small pediatric samples.
Anti-vector Neutralizing Antibody Assay
One day prior to performing the assay, GripTite 293 cells (Invitrogen)
were seeded in 96-well plates (3 104 cells/well). Heat inactivated test
samples were diluted 4-fold from 1:9 to 1:2,304 in 10% FBS in DMEM
and incubated 1:1 with ChAd63 expressing the secreted alkaline
phosphatase gene (8  107 vp/mL) for 1 hr at 37C. Serum and virus
were then added to 293 cells in a volume of 200 mL in duplicate for
1 hr, after which sample and virus were aspirated and replaced with
fresh 10% FB DMEM. A virus-only control was included. After
22–26 hr at 37C, 50 mL of medium was assayed for SEAP activity us-
ing a Phospha-Light TROPIX phosphatase assay (Applied Bio-
systems) in black assay plates, and luminescence was measured after
45 min on a Thermo-Fisher Varioskan Flash Luminometer. Anti-vec-
tor neutralization titers were deﬁned as the dilution of serum showing
50% reduction in SEAP activity, based on observed % inhibition
values relative to SEAP activity from virus alone. For trial A, anti-vec-
tor antibodies were measured in serum and for trial B plasma was
used, however, we have determined that these sample types are equiv-
alent for this assay.
TRAP-Specific Total IgG ELISA
Standardized ELISAs for TRAP-speciﬁc antibodies were conducted
as previously described35. Brieﬂy, a reference standard of pooled
anti-TRAP antibody positive serum was serially diluted to produce
a standard curve, which was included on all plates. The standard sam-
ple was assigned a value in arbitrary ELISA units (EUs). The standard
curve was then used to convert absorbance values of individual test
sera (diluted to fall within the linear range of the curve) into EUs.
A “seropositive cut-off” value was calculated using the mean plus
three standard deviations of the EU values of 42 serum samples
from unvaccinated UK volunteers. For the total IgG standardized
ELISA, this cut-off value was 88 EUs.
TRAP-Specific Isotype ELISA
Isotype ELISAs were conducted as previously described53 except
plates were coated with 0.5 mg/mL of TRAP antigen in carbon-
ate-bicarbonate coating buffer and left overnight at 4C. Brieﬂy,
sera were diluted 1:100 in 0.2% BSA in PBS/Tween-20 (dilution
buffer) and added in duplicate to each of six 96-well plates. After
2 hr, plates were washed and one of six secondary antibodies was
added to each plate at 1:1,000 in dilution buffer, 50 mL per well.
Secondary antibodies used were: biotin-conjugated mouse anti-hu-
man IgG1 Fc (clone HP6070) (Life Technologies); biotin-conju-
gated mouse anti-human IgG2 Fc (clone HP6002) (Life Technolo-
gies); biotin-conjugated mouse anti-human IgG3 (clone HP6050)
(Sigma); biotin-conjugated mouse anti-human IgG4 (clone
HP6025) (Sigma); alkaline phosphatase-conjugated goat polyclonal
anti-human IgA a-chain (Sigma); and biotin-conjugated goat poly-
clonal anti-human IgM u-chain (Sigma). After 1 hr, plates were
washed and 50 uL of ExtrAvidin alkaline phosphatase (Sigma)
diluted 1:5,000 in dilution buffer was added to all plates (except
IgA, to which only dilution buffer was added). After 30 min, all
plates were washed and development buffer was added as for total
IgG ELISA. Blank wells and internal development controls were
included on each plate.
A “seropositive cut-off” value was calculated for each isotype or sub-
class using the mean plus 3 SDs of the EU values of 42 serum samples
from unvaccinated UK volunteers. Cut-off values were 0.147 (IgG1),
0.166 (IgG2), 0.2002 (IgG3), 0.151 (IgG4), 0.362 (IgM), and 0.374
(IgA).
TRAP-Specific IgG Avidity ELISA
IgG antibody avidity was assessed by sodium thiocyanate (NaSCN)-
displacement ELISA. The assays were conducted as for total IgG
ELISAs except that sera were individually diluted in dilution buffer
to a level calculated to reach an OD405 of 1.0 (using total IgG EUs)
and plated at 50 mL/well in 16 wells of a 96-well plate. Plates were
incubated for 2 hr at room temperature (RT) before chaotropic agent
NaSCNwas added in duplicate at increasing concentrations down the
plate (0–7 Molar [M]). Plates were incubated for 15 min at RT before
washing, incubation with secondary antibody and development as for
the total IgG assay. The concentration of NaSCN required to reduce
the OD405 to 50% of that without NaSCN ( = IC50) was used as a
measure of avidity. This was calculated from the intercept of the curve
for each sample with the line of 50% reduction of the OD405 in the
NaSCN-free well for each sample.
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IgG1 and IgG3 avidity was assessed using the same protocol, except
that two dilutions were made for each sample to levels calculated to
reach an OD405 of 1.0 (using the OD values from the IgG1 and
IgG3 ELISAs) and added to two plates, one of which was incubated
with anti-IgG1 and the other with anti-IgG3. Secondary antibodies
used were the same as used for the Isotype ELISAs.
Statistical Methods
Group data display geometric mean or median. Matched pairs ana-
lyses were conducted where time points within a group were
compared and excludes volunteers with missing data at any time
point. UK and Gambian adult data were combined for several
ELISpot and ELISA analyses due to no statistically signiﬁcant differ-
ences between the two populations. A Kruskal-Wallis test was used to
compare ELISpot and ELISA data in children against the adult control
group, with Dunn’s multiple comparisons post-test. Kruskal-Wallis
tests for comparisons between all groups were also used, with Dunn’s
multiple comparisons post-test. For statistical analyses, an alpha-level
of 0.05 was considered signiﬁcant and all p values are two-tailed. All
analyses were performed in GraphPad Prism, Mac version 6.
(GraphPad Software).
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